Deal includes microarray systems, high-throughput screening instruments, genetic-expression profilers, and exome sequencing technologies.
Roche will furnish two University of California, Los Angeles (UCLA) research centers with technologies as well as reagent and bioinformatics support for the discovery of biomarkers. Roche and UCLA say that their scientists will work collaboratively on early-stage research, with an initial focus on developing better technologies for academic and commercial use.
Under the agreement, Roche will also provide scientists at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA as well as UCLA’s Jonsson Comprehensive Cancer Center with latest-generation microarray systems from Roche NimbleGen, high-throughput screening instruments, genetic expression profilers, and exome-sequencing technologies.
UCLA researchers will submit project applications for research using these technologies. An advisory committee of Roche and UCLA scientists will review the submissions and select those deemed to make the best use of the technologies and are most likely to succeed.